Lion's Mane and Amyloid Beta: Mechanisms of Neuroprotection

Lion's Mane and Alzheimer's Disease

3 Alzheimer's hallmarks addressed: amyloid plaques, tau tangles, and neuroinflammation

Erinacine A-enriched mycelium reduced amyloid-beta plaque deposition and tau phosphorylation in APP/PS1 transgenic mice. Polysaccharides suppress neuroinflammation via NF-kB inhibition. All evidence is preclinical.

Tsai-Teng et al., 2016; Spangenberg et al., 2025

GSK-3β

the kinase that hyperphosphorylates tau protein in Alzheimer's disease; erinacines inhibit this kinase, explaining how lion's mane addresses both amyloid and tau pathology (Tsai-Teng et al., 2016)

BBB crossing

erinacines from the mycelium cross the blood-brain barrier directly; hericenones from the fruiting body do not as readily, explaining why mycelium extracts are most relevant for neuroprotection (Li et al., 2018)

0 human trials

no randomized controlled trial has tested lion's mane against amyloid plaques or tau in human Alzheimer's patients; all direct neuroprotection evidence is from transgenic mouse and cell models

Tsai-Teng et al., 2016; Spangenberg et al., 2025

View as image ↗

Alzheimer's disease has two defining molecular hallmarks. The first is amyloid beta plaques: clusters of misfolded protein fragments that accumulate between neurons and disrupt communication. The second is neurofibrillary tangles: tau protein that becomes hyperphosphorylated, collapses into insoluble threads, and kills neurons from the inside. Most Alzheimer's drug development has targeted one or the other. Lion's mane addresses both, plus the chronic neuroinflammation that accelerates both processes, through different compounds.

This is not hype. The evidence is preclinical, meaning it comes from mouse models and cell cultures rather than human clinical trials. But the mechanisms are specific, the targets are biologically relevant, and a 2025 systematic review of the full preclinical evidence base confirmed multiple neuroprotective pathways. For the broader overview of what lion's mane is and does, see what is lion's mane mushroom: a science-based overview.

The Three Targets: How Lion's Mane Addresses Alzheimer's Disease Biology

Alzheimer's drug development history is largely the story of targeting amyloid beta plaques. The amyloid hypothesis dominated for decades: clear the plaques, treat the disease. Multiple billion-dollar drug programs failed on this hypothesis before partial successes emerged with anti-amyloid monoclonal antibodies.

What made the amyloid-only approach limited was the parallel tau pathology. Even in patients where amyloid plaques are cleared, tau tangles continue to spread, neurons continue to die, and cognitive decline continues. And beneath both processes, chronic neuroinflammation drives the disease forward regardless of amyloid clearance.

Lion's mane addresses all three problems through different compounds. Erinacines from the mycelium target amyloid beta formation and tau hyperphosphorylation through kinase inhibition. Polysaccharides target neuroinflammation through NF-kB pathway suppression. NGF upregulation supports neuron survival and connectivity regardless of pathological mechanism. This multi-target profile is what distinguishes lion's mane from single-target pharmaceutical approaches, at least in preclinical data.

Erinacine A and Amyloid Beta: The 2016 Transgenic Mouse Evidence

Tsai-Teng and colleagues (2016) conducted what remains the most-cited lion's mane Alzheimer's study: a controlled experiment using APP/PS1 transgenic mice, the standard animal model for Alzheimer's research.^[2]

APP/PS1 mice carry mutations in the human amyloid precursor protein and presenilin-1 genes that cause them to develop amyloid plaques and cognitive decline on an accelerated timeline. They are the closest available animal approximation of human Alzheimer's pathology.

The intervention: erinacine A-enriched mycelium of H. erinaceus, given by mouth for 30 days to the transgenic mice. The results showed reduced amyloid-beta plaque deposition in the brains of treated animals compared to controls. Alongside the plaque reduction, the study found restored spatial memory performance on behavioral tests, reduced tau phosphorylation, and increased expression of insulin-degrading enzyme, which promotes amyloid clearance.

The mechanism Spangenberg and colleagues (2025) identified in their systematic review of erinacine preclinical evidence involves two parallel actions: erinacines inhibit the secretase enzymes that cleave amyloid precursor protein into amyloid-beta fragments, reducing production; and they promote the expression of proteins that clear existing amyloid beta from brain tissue.^[1] Reducing production while increasing clearance produces the net reduction seen in the Tsai-Teng (2016) transgenic model.

Flagship Study

Tsai-Teng et al. (2016) · Journal of Biomedical Science

Population

APPswe/PS1dE9 transgenic mice (standard Alzheimer's model)

Intervention

Erinacine A-enriched H. erinaceus mycelium, oral, 30 days

Comparator

Untreated transgenic controls

Finding

Attenuated cerebral amyloid-beta plaque burden, reduced tau phosphorylation, raised insulin-degrading enzyme, and restored spatial memory.

positive Preclinical only. A robust positive result in a transgenic mouse model, not evidence of benefit in human patients.

Tsai-Teng et al. (2016), Journal of Biomedical Science

Tau: The Second Hallmark and GSK-3Beta Inhibition

Amyloid beta plaques are what most people associate with Alzheimer's, but tau tangles are what kill neurons. Tau is a protein that normally stabilizes microtubules inside neurons. When it becomes hyperphosphorylated (when too many phosphate groups attach to the tau protein chain), it detaches from microtubules, misfolds, and forms insoluble tangles that disrupt neuron function and cause cell death.

The kinase primarily responsible for tau hyperphosphorylation is GSK-3beta (glycogen synthase kinase-3 beta). Inhibiting GSK-3beta is one of the main strategies in tau-targeting Alzheimer's drug development.

Erinacines inhibit GSK-3beta activity. This is the mechanistic link between lion's mane and tau pathology: by reducing GSK-3beta activity, erinacines reduce the rate of tau hyperphosphorylation, potentially slowing tangle formation. The Tsai-Teng (2016) study documented reduced tau phosphorylation in the APP/PS1 transgenic mice in addition to amyloid reduction, consistent with this mechanism.^[2]

Rodriguez and colleagues (2022) went further, testing lion's mane specifically in the rTg4510 mouse model, a transgenic model that develops tau pathology more selectively than APP/PS1 mice.^[3] This is significant because it establishes that lion's mane produces effects in a tau-specific model, not only in combined amyloid-tau models like APP/PS1. The evidence for tau neuroprotection is not just a secondary effect in amyloid models; it appears in tau-specific experimental contexts as well.

Neuroinflammation: The Third Target via Polysaccharides

Amyloid plaques and tau tangles do not operate in a vacuum. Chronic neuroinflammation accelerates both processes: activated microglia (the brain's immune cells) release inflammatory cytokines that increase amyloid production, promote tau hyperphosphorylation, and kill neurons directly through inflammatory stress.

Lion's mane contains polysaccharides, distinct from the erinacine diterpenes responsible for amyloid and tau effects, that suppress neuroinflammatory signaling. Contato and colleagues' 2025 narrative review summarized evidence that lion's mane polysaccharides inhibit NF-kB pathway activation and reduce production of TNF-alpha and IL-6, two primary pro-inflammatory cytokines implicated in Alzheimer's neuroinflammation.^[4]

NF-kB is the master transcription factor that drives inflammatory gene expression in the brain. Inhibiting it reduces the production of the inflammatory mediators that accelerate Alzheimer's pathology. This is a genuinely different mechanism from the erinacine-based amyloid and tau effects; the polysaccharides and the diterpenes target different molecular processes.

The practical implication of this multi-compound profile: a product using only erinacine-enriched mycelium delivers the amyloid and tau mechanisms but may miss the polysaccharide-driven anti-inflammatory pathway. Full-spectrum preparations covering both the mycelium (erinacines) and the fruiting body (polysaccharides, hericenones) potentially cover more of the neuroprotective profile.

Why Erinacines Cross the Blood-Brain Barrier and Hericenones Do Not

A critical pharmacological distinction between lion's mane's two main compound classes is their ability to reach the brain.

Li and colleagues (2018) reviewed the neurohealth properties of erinacine-enriched mycelium and the question of how these compounds reach the central nervous system, noting that among lion's mane's compounds erinacine A has the best-confirmed pharmacological action inside the brain.^[6] Erinacines are lipophilic (fat-soluble) molecules. The blood-brain barrier is primarily a lipid membrane. Lipophilic molecules cross it by passive diffusion. This is why erinacines can directly stimulate NGF production in brain cells: they physically reach those cells after absorption.

Hericenones from the fruiting body are less lipophilic. They are biologically active in peripheral tissue and can upregulate NGF via indirect mechanisms (through signaling in the gut and peripheral nervous system), but their direct access to brain tissue is more limited compared to erinacines.

For the specific neuroprotective mechanisms that require direct action on brain cells (inhibiting secretases that produce amyloid beta, inhibiting GSK-3beta in neurons, upregulating amyloid clearance enzymes), erinacines from the mycelium are the relevant compounds. Products made from mycelium specifically, or from erinacine-enriched mycelium concentrates, are what the preclinical neuroprotection evidence actually tested. For a deep dive into erinacines specifically, see erinacines: the compounds that cross the blood-brain barrier.

The 2025 Systematic Review: What Spangenberg et al. Found

Spangenberg and colleagues (2025) published a systematic review specifically examining the neuroprotective effects of erinacines across preclinical models.^[1] This is the most comprehensive synthesis of the erinacine neuroprotection evidence to date.

The review confirmed multiple documented neuroprotective mechanisms: NGF and BDNF upregulation, amyloid-beta reduction through secretase inhibition and enhanced clearance, tau dephosphorylation via GSK-3beta inhibition, and anti-neuroinflammatory activity. Across the preclinical models reviewed, the evidence for each of these mechanisms was consistent.

The review also identified the key limitation that honest coverage requires stating explicitly: virtually all mechanistic evidence is from animal models and cell cultures. The human evidence for lion's mane in Alzheimer's is limited to the Mori 2009 randomized controlled trial in mild cognitive impairment patients (a preclinical Alzheimer's stage), which showed cognitive improvement but did not directly measure amyloid plaques or tau tangles.^[8] No randomized clinical trial has tested erinacines against amyloid pathology or tau pathology in human Alzheimer's patients.

Cornford and colleagues (2025) similarly reviewed the evidence for lion's mane as a future therapeutic for Alzheimer's prevention and management, concluding that the preclinical foundation is scientifically compelling while emphasizing that translation to human clinical evidence remains the critical next step.^[5]

The NGF Foundation: Mori 2008 and the Cellular Basis

Before any of the Alzheimer's-specific evidence existed, Mori and colleagues (2008) established the cellular foundation: among four edible mushrooms tested, only H. erinaceus extract promoted NGF gene expression in human astrocyte (1321N1 astrocytoma) cells, and it did so concentration-dependently.^[7]

This is the upstream mechanism that connects to the neuroprotection story. NGF is not only a growth factor for developing neurons. In the adult brain, it maintains the cholinergic neurons of the basal forebrain that are among the first casualties of Alzheimer's disease. These cholinergic neurons project to the hippocampus and cortex and support memory encoding and recall. They are exquisitely sensitive to NGF availability.

When NGF levels decline in aging and early Alzheimer's disease, basal forebrain cholinergic neurons atrophy and eventually die. This is the mechanistic basis for why acetylcholinesterase inhibitors (the standard Alzheimer's drug class) slow decline by preserving acetylcholine; it is also why NGF upregulation through lion's mane could provide an upstream preventive effect. Maintaining cholinergic neuron health through NGF support is an approach that works at an earlier stage of the disease cascade than clearing plaques after they form. For more on the NGF mechanism specifically, see hericenones and NGF synthesis: how lion's mane stimulates nerve growth.

The Evidence Level: What Preclinical Means for Patients and Families

Every amyloid beta and tau finding reviewed above comes from animal models (primarily transgenic mice) or cell cultures. This matters for how to interpret the evidence.

Transgenic mouse models of Alzheimer's are the best available preclinical tools for testing neuroprotection mechanisms. They are not humans. Mouse brains are smaller, mouse Alzheimer's progression is accelerated, and interventions that succeed in mice frequently fail in human trials. The history of Alzheimer's drug development is filled with compounds that cleared plaques in mice and did nothing in humans.

What the preclinical evidence establishes is biological plausibility: lion's mane contains compounds that interact with the correct molecular targets in the correct directions. The erinacines inhibit the right enzymes, in the right animal models, with measurable effects on the relevant pathology. This is a stronger scientific foundation than many compounds that have entered clinical trials.

What the preclinical evidence does not establish is whether these effects will translate to meaningful benefits in human Alzheimer's patients. That requires randomized controlled trials in human populations, which have not yet been conducted for the specific neuroprotection endpoints. The human clinical evidence for lion's mane in cognitive function is real (Mori 2009^[8]; Docherty 2023^[9]), but it measures general cognitive scores rather than amyloid plaque burden or tau tangle density.

Evidence Review

1. Cell studiescompleted

   H. erinaceus induces NGF in human astrocytoma cells (Mori 2008)

2. Animal modelscurrent

   Amyloid, tau, and neuroinflammation endpoints in transgenic mice (Tsai-Teng 2016; Rodriguez 2022)

3. Small human trialsmissing

   Human trials exist for cognition (Mori 2009; Docherty 2023) but none measure amyloid or tau

4. Large RCTsmissing

   No RCT tests erinacines against amyloid or tau pathology

5. Meta-analysesmissing

   Not possible until amyloid/tau human trials exist

For amyloid and tau endpoints specifically, the evidence stops at animal models. The human trials that exist measured cognitive scores, not plaque or tangle burden.

Spangenberg et al. (2025); Tsai-Teng et al. (2016); Mori et al. (2009)

Safety

Preclinical evidence is not a treatment recommendation

Every amyloid and tau finding here comes from mice or cell cultures. Compounds that cleared plaques in mice have repeatedly failed in human Alzheimer's trials, so animal results cannot be read as proof of human benefit.

Lion's mane is not a treatment for Alzheimer's disease. This article describes mechanisms, not medical advice. Anyone with memory concerns or a diagnosis should be evaluated by a physician, and supplements should not replace prescribed care.

Particularly relevant for: People with Alzheimer's disease, mild cognitive impairment, or memory concerns

Discuss any supplement with your doctor before use, especially alongside prescribed medications.

The Bottom Line

Lion's mane addresses three Alzheimer's disease hallmarks through different compounds: erinacines reduce amyloid-beta through secretase inhibition and enhanced clearance (Tsai-Teng 2016, Spangenberg 2025), and inhibit GSK-3beta to reduce tau hyperphosphorylation (confirmed in the rTg4510 tau model by Rodriguez 2022); polysaccharides suppress neuroinflammation via NF-kB inhibition (Contato 2025). Erinacines cross the blood-brain barrier directly because of their lipophilic structure, making mycelium-specific extracts the pharmacologically relevant form for these mechanisms (Li 2018). All amyloid/tau neuroprotection evidence is preclinical; no RCT has tested lion's mane against amyloid or tau pathology in human Alzheimer's patients.

Frequently Asked Questions

How does lion's mane affect amyloid beta?

Erinacines from lion's mane mycelium reduce amyloid-beta through two parallel actions: they inhibit the secretase enzymes that cleave amyloid precursor protein into amyloid-beta fragments, reducing production, and they promote expression of amyloid-clearing enzymes like insulin-degrading enzyme, increasing clearance. Tsai-Teng and colleagues (2016) documented reduced amyloid plaque deposition in APP/PS1 transgenic Alzheimer's mice treated with erinacine A-enriched mycelium. All evidence is from animal models; no human trial has measured amyloid plaque changes.

Does lion's mane reduce amyloid plaques?

In transgenic Alzheimer's mice, yes. Tsai-Teng et al. (2016) found that erinacine A-enriched mycelium reduced amyloid-beta plaque deposition and restored spatial memory. Spangenberg et al.'s 2025 systematic review confirmed this across multiple preclinical models. No randomized controlled trial has tested whether lion's mane reduces amyloid plaques in human Alzheimer's patients. The preclinical evidence is mechanistically sound but not yet translated to human clinical endpoints.

What is the mechanism of lion's mane neuroprotection?

Five documented mechanisms: (1) NGF/BDNF upregulation through erinacines, supporting neuron survival; (2) amyloid-beta reduction through secretase inhibition and enhanced clearance; (3) tau dephosphorylation via GSK-3beta inhibition; (4) NF-kB pathway suppression reducing TNF-alpha and IL-6 neuroinflammation; (5) antioxidant protection of neurons from oxidative stress. The first four mechanisms involve erinacines from the mycelium; the anti-inflammatory mechanism involves polysaccharides; both require direct brain access, which erinacines achieve more readily due to their lipophilic structure.

How does erinacine A work against Alzheimer's?

Erinacine A is a diterpene from lion's mane mycelium that crosses the blood-brain barrier directly due to its lipophilic structure. Inside the brain, it inhibits beta- and gamma-secretase enzymes that generate amyloid-beta from amyloid precursor protein. It also inhibits GSK-3beta, the kinase that hyperphosphorylates tau protein into tangles. And it promotes expression of NGF, maintaining the basal forebrain cholinergic neurons that are among the earliest casualties of Alzheimer's disease.

Does lion's mane affect tau protein?

Yes, in preclinical models. Erinacines inhibit GSK-3beta, the primary kinase responsible for tau hyperphosphorylation. Tsai-Teng et al. (2016) found reduced tau phosphorylation in APP/PS1 transgenic mice treated with erinacine A mycelium. Rodriguez et al. (2022) specifically tested lion's mane in the rTg4510 tau mouse model (a model that develops tau pathology selectively) and documented neuroprotective effects. No human trial has tested lion's mane against tau pathology in Alzheimer's patients.

Sources & References

1. 1RTHM-02184·Spangenberg, E T et al. (2025). “Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models..” Frontiers in pharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00452·Tsai-Teng, Tzeng et al. (2016). “Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice..” Journal of biomedical science.Study breakdown →PubMed →↩
3. 3RTHM-01610·Rodriguez, Mya N et al. (2022). “Lion's Mane (Hericium erinaceus) Exerts Anxiolytic Effects in the rTg4510 Tau Mouse Model..” Behavioral sciences (Basel.Study breakdown →PubMed →↩
4. 4RTHM-00921·Contato, Alex Graça et al. (2025). “Lion's Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential-A Narrative Review..” Nutrients.Study breakdown →PubMed →↩
5. 5RTHM-00922·Cornford, Nisha et al. (2025). “Hericium erinaceus: A possible future therapeutic treatment for the prevention and delayed progression of Alzheimer's disease? - A narrative review..” Nutrition research reviews.Study breakdown →PubMed →↩
6. 6RTHM-00973·Li, I-Chen et al. (2018). “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines..” Behavioural neurology.Study breakdown →PubMed →↩
7. 7RTHM-00268·Mori, Koichiro et al. (2008). “Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells..” Biological & pharmaceutical bulletin.Study breakdown →PubMed →↩
8. 8RTHM-00165·Mori, Koichiro et al. (2009). “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial..” Phytotherapy research : PTR.Study breakdown →PubMed →↩
9. 9RTHM-00821·Docherty, Sarah et al. (2023). “The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study..” Nutrients.Study breakdown →PubMed →↩